US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Pfizer (NY:PFE)

27.80 -0.32 (-1.14%)
Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Stock Market Today, Aug. 19: Moderna Skyrockets 177% on Positive Phase 3 Melanoma Data ↗
Today, Aug. 19, 2026, Moderna's personalized cancer vaccine met its late-stage goal, with the company and Merck planning an FDA submission. 
Via The Motley Fool
Topics Stocks
News headline image
Why Pfizer (PFE) Stock Is Trading Up Today
What Happened? Shares of global pharmaceutical company Pfizer (NYSE:PFE) jumped 3.8% in the afternoon session after positive clinical trial results from peer... 
Via StockStory
Topics World Trade
News headline image
Merck Just Raised the Stakes for Pfizer's Cancer Vaccine Ambitions ↗
Merck's deeper push into personalized cancer vaccines raises the competitive bar for Pfizer, BioNTech in biotech's fastest-growing race. 
Via Benzinga
What's going on in today's session: S&P500 most active stocks ↗
Via Chartmill
News headline image
Pfizer Stock Rises Wednesday: What's Going On? ↗
Pfizer Inc (NYSE:PFE) shares are trading higher Wednesday, moving in sympathy with mRNA cancer vaccine-related companies after Merck & Co Inc (NYSE:MRK) and Moderna Inc (NASDAQ:MRNA) announced that... 
Via Benzinga
News headline image
Protalix (PLX) Q2 2026 Earnings Call Transcript ↗
Elfabrio sales surge drives $19.9M quarterly revenue and $22.1M H1 net income. 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
3 S&P 500 Stocks We Keep Off Our Radar
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
Via StockStory
Topics Fraud Stocks
Curious about the most active S&P500 stocks in today's session? ↗
Via Chartmill
News headline image
Warren Buffett and Greg Abel Keep Overlooking This Stock -- but It's One of the Most Berkshire-Ready Picks on the Market ↗
Even if Berkshire Hathaway never scoops up a stake on this largely overlooked and mostly unloved name, that doesn't mean it doesn't have a place in your portfolio. 
Via The Motley Fool
News headline image
2 Profitable Stocks with Solid Fundamentals and 1 We Ignore
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
News headline image
3 Stocks Under $50 We’re Skeptical Of
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However... 
Via StockStory
These S&P500 stocks are the most active in today's session ↗
Via Chartmill
News headline image
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗
Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think. 
Via The Motley Fool
News headline image
European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application ↗
Valneva (VALN) stock surges after EMA validates MAA for Lyme disease vaccine candidate developed with Pfizer (PFE). Phase 3 trial showed efficacy and no safety concerns, pending regulatory approval. 
Via Benzinga
News headline image
Recent Filing Shows That Rep. Carol Miller Sold Over $60K Worth of Pfizer Stock ↗
A August filing shows that Representative Carol Miller reported a sale in Pfizer (NYSE:PFE), valued between $60,004 and $200,000. The transaction date is listed as March 10, 2025, with the report... 
Via Benzinga
News headline image
Vanguard Is "Cautious" on U.S. Growth Stocks. These 2 Value ETFs Could Be Smarter Buys for Long-Term Investors. ↗
In the next 10 years, underrated sectors and undervalued companies might beat the biggest names of the AI trade. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
From Pfizer Inc.
Via Business Wire
News headline image
Valneva Q2 Earnings Call Highlights ↗
Valneva (NASDAQ:VALN) reported lower first-half revenue and wider losses for 2026, while maintaining its full-year sales outlook and emphasizing its cash position, restructuring measures and... 
Via MarketBeat
Topics Earnings
What's going on in today's session: S&P500 most active stocks ↗
Via Chartmill
News headline image
2 Large-Cap Stocks for Long-Term Investors and 1 We Avoid
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are... 
Via StockStory
Which S&P500 stocks are the most active on Wednesday? ↗
Via Chartmill
News headline image
Rigel (RIGL) Q2 2026 Earnings Call Transcript ↗
VEPPANU launch and R289 data readouts drive second-half priorities. 
Via The Motley Fool
Topics Earnings
News headline image
Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock ↗
This problem has a solution, and Pfizer is implementing it. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Arvinas (ARVN) Q2 2026 Earnings Call Transcript ↗
VEPPANU's FDA approval and $50 million Pfizer milestone fuel record net income. 
Via The Motley Fool
Topics Earnings
Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. ↗
Via Chartmill
News headline image
Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026? ↗
Both of these stocks pay more than double the S&P 500 average of 1.1%. 
Via The Motley Fool
Topics Stocks
News headline image
BioNTech (BNTX) Q2 2026 Earnings Call Transcript ↗
COVID vaccine demand weakens as BioNTech pivots to oncology with promising clinical data. 
Via The Motley Fool
Topics Earnings
News headline image
Pfizer (PFE) Q2 2026 Earnings Call Transcript ↗
Non-COVID products surge 5% as Pfizer raises guidance and targets $9.7B in savings. 
Via The Motley Fool
Topics Earnings
News headline image
5 Insightful Analyst Questions From Pfizer’s Q2 Earnings Call
Pfizer’s second quarter results reflected stability in its core business despite ongoing challenges in COVID-related product demand. The company’s performanc... 
Via StockStory
Topics Earnings
News headline image
BridgeBio Pharma Q2 Earnings Call Highlights ↗
BridgeBio Pharma (NASDAQ:BBIO) reported continued growth for its ATTR cardiomyopathy treatment Attruby in the second quarter of 2026, while advancing three late-stage programs into regulatory review... 
Via MarketBeat
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >